Metastasized breast cancer now has a new therapy on the market, though it remains to be seen whether noticeably dangerous side effects may prevent widespread use. Trastuzumab emtansine (T-DM1) or Kadcyla, produced by Immunogen [Nasdaq: IMGN], is a treatment that targets the HER2 protein.
Last month, Santarus, Inc’s Uceris for ulcerative colitis received FDA approval, and the company has announced a planned launch in March 2013. Santaurs has already begun adding 85 new positions to its sales staff in anticipation of Uceris’ future. The Uceris approval hopes to promise strong returns for a company with a checkered past, but a promising future.
The US Food and Drug advisory panel has voted for the preliminary approval of Invokana (canagliflozin), Johnson and Johnson’s new type 2 diabetes drug, in […]
Alexza Pharmaceuticals Inc. [NASDAQ: ALXA] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of ADASUVE, being developed […]
Hemispherx Biopharma [NYSE: HEB] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) concerning the approval status of Ampligen (poly Izpoly C12U), […]
China Nuokang Bio-Pharmaceutical Inc. [NASDAQ: NKBP] has announced that the company plans to release third quarter 2012 financial results on Sunday, November 25, 2012. Nuokang […]
Medivation, Inc [Nasdaq: MDVN] today announced that it has effected a 2-for-1 forward split of all shares of its common stock and increased the authorized […]
NPS Pharmaceuticals expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of GATTEX, being developed for the treatment of adult short bowel syndrome.
Santarus, Inc. expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of UCERIS, being developed for the treatment […]
Supernus Pharmaceuticals [Nasdaq: SUPN] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of SPN-804, being developed for […]
Copyright © 2025 | WordPress Theme by MH Themes